Skip to main content

Table 1 Baseline characteristics

From: Nebulised amphotericin B to eradicate Candida colonisation from the respiratory tract in critically ill patients receiving selective digestive decontamination: a cohort study

Characteristics

Nebulised amphotericin B (n = 59)

Standard care (n = 274)

P value

Age

63 (43–76)

63 (52–72)

0.78

Gender male

43 (73)

189 (69)

0.55

APACHE IV score

77 (60–96)

75 (58–92)

0.42

Corticosteroid usea

18 (31)

75 (27)

0.63

SOFA scoreb

6 (3–8)

5 (3–8)

0.51

Days in ICU before onset of the colonisation episode

0 (0–2)

1 (0–3)

0.24

Candida load in sputum (CFUs)c

  

<0.001

<10

9 (15)

117 (43)

10-100

32 (54)

102 (37)

>100

18 (31)

55 (20)

Candida colonisation of the oropharynx

50 (85)

213 (78)

0.23

Candida colonisation of the rectum

23 (39)

75 (27)

0.08

Delay between onset of Candida colonisation in sputum and NAB start

5 (4–7)

NA

NA

Bacterial co-colonisation in sputum:

   

Gram-negative rodsd

13 (22)

83 (30)

0.20

Pseudomonas species

1 (2)

20 (7)

0.11

Gram-positive cocci

13 (22)

63 (23)

0.87

  1. aCorticosteroid use was defined as a daily dose >100 mg hydrocortisone or equivalent; bwe used a modified sum score, excluding points for the central nervous system; cCandida load at baseline was determined by semi-quantitative culture; dGram-negative rods including Pseudomonas species. APACHE, Acute Physiology and Chronic Health Evaluation; CFU, colony-forming units; ICU, intensive care unit; NA, not applicable; SDD, selective digestive decontamination; SOD, selective oral decontamination; SOFA, Sequential Organ Failure Assessment. Data are presented as medians (interquartile range (IQR)) or absolute numbers (%).